5:38 PM
 | 
Sep 24, 2012
 |  BC Extra  |  Clinical News

Novartis reports RLX030 data in acute heart failure

Novartis AG (NYSE:NVS; SIX:NOVN) said RLX030 plus standard of care (SOC) met one of two co-primary endpoints measuring a reduction in dyspnea in the Phase III RELAX-AHF trial to treat acute heart failure (AHF). The endpoints were: the change from baseline in...

Read the full 196 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >